IN2012DN03128A - - Google Patents

Download PDF

Info

Publication number: IN2012DN03128A
Authority: IN; India
Prior art keywords: compositions; eye; active ingredient; treatment; group
Prior art date: 2009-12-14

Application number

Other languages

English (en)

Inventor

Bastian Theisinger

Sonja Theisinger

Bernhard Gunther

Original Assignee

Novaliq Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-14

Filing date

2010-12-13

Publication date

2015-09-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-12-13 Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh

2015-09-18 Publication of IN2012DN03128A publication Critical patent/IN2012DN03128A/en

Links

239000000203 mixture Substances 0.000 abstract 2
208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
206010013774 Dry eye Diseases 0.000 abstract 1
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
229960003444 immunosuppressant agent Drugs 0.000 abstract 1
239000003018 immunosuppressive agent Substances 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IN3128DEN2012 2009-12-14 2010-12-13 IN2012DN03128A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP09015423A EP2335735A1 (fr)	2009-12-14	2009-12-14	Composition pharmaceutique pour le traitement de la kératoconjonctivite sèche
PCT/EP2010/069495 WO2011073134A1 (fr)	2009-12-14	2010-12-13	Composition pharmaceutique pour le traitement du syndrome de l'oeil sec

Publications (1)

Publication Number	Publication Date
IN2012DN03128A true IN2012DN03128A (fr)	2015-09-18

Family

ID=41731659

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN3128DEN2012 IN2012DN03128A (fr)	2009-12-14	2010-12-13

Country Status (15)

Country	Link
US (1)	US8614178B2 (fr)
EP (2)	EP2335735A1 (fr)
JP (5)	JP5663595B2 (fr)
KR (2)	KR101652714B1 (fr)
CN (1)	CN102652022B (fr)
AU (1)	AU2010333039B2 (fr)
BR (3)	BR112012014190B8 (fr)
CA (2)	CA2776860C (fr)
DK (1)	DK2512515T3 (fr)
ES (1)	ES2449308T3 (fr)
IN (1)	IN2012DN03128A (fr)
MX (1)	MX2012006720A (fr)
PL (1)	PL2512515T3 (fr)
PT (1)	PT2512515E (fr)
WO (1)	WO2011073134A1 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010256558B2 (en)	2009-06-03	2013-10-03	Forsight Labs, Llc	Anterior segment drug delivery
US10045996B2 (en)	2010-03-17	2018-08-14	Novaliq Gmbh	Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (fr)	2010-10-20	2012-04-25	Novaliq GmbH	Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr)	2010-11-11	2012-06-13	Novaliq GmbH	Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
DK2714008T3 (en)	2011-05-25	2017-03-13	Novaliq Gmbh	PHARMACEUTICAL COMPOSITION FOR APPLICATION ON NAIL
EP2714010B1 (fr)	2011-05-25	2017-03-01	Novaliq GmbH	Composition pharmaceutique a base d'alcanes semifluoré
ES2625538T3 (es)	2012-01-23	2017-07-19	Novaliq Gmbh	Composiciones de proteínas estabilizadas basadas en alcanos semifluorados
CN104619314B (zh)	2012-09-12	2017-09-22	诺瓦利克有限责任公司	包含半氟化烷烃的混合物的组合物
BR112015005008B1 (pt)	2012-09-12	2022-04-19	Novaliq Gmbh	Composições de alcano semifluorado
EP2708228B1 (fr)	2012-09-12	2018-05-16	Novaliq GmbH	Compositions de lavage oculaire
EP2730291A1 (fr) *	2012-11-09	2014-05-14	Fluoron Gmbh	Composition de tamponnade interne
WO2014117035A1 (fr)	2013-01-24	2014-07-31	Transderm, Inc.	Compositions pour une administration transdermique d'inhibiteurs de mtor
JP6304475B2 (ja) *	2013-01-31	2018-04-04	ロート製薬株式会社	点眼剤
CN105073112B (zh)	2013-03-13	2017-12-29	参天制药株式会社	睑板腺功能障碍的治疗剂
CN114028560A (zh) *	2013-07-23	2022-02-11	诺瓦利克有限责任公司	稳定的抗体组合物
CA2927321A1 (fr) *	2013-10-15	2015-04-23	Forsight Vision5, Inc.	Preparations et methodes permettant d'augmenter ou de reduire le mucus
US20200237859A1 (en)	2019-01-25	2020-07-30	Newport Research, Inc.	Aqueous suspensions of cyclosporin
US11324800B2 (en)	2015-01-15	2022-05-10	Wellspring Ophthalmics, Inc.	Aqueous suspensions of cyclosporin
US20160296532A1 (en)	2015-04-13	2016-10-13	Forsight Vision5, Inc.	Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11013403B2 (en) *	2015-09-29	2021-05-25	The Regents Of The University Of California	Methods of diagnosing diseases of mucosal surfaces
CN113662929A (zh) *	2015-09-30	2021-11-19	诺瓦利克有限责任公司	用于眼部给药的半氟化化合物
CN108348777B (zh)	2015-09-30	2020-04-28	诺瓦利克有限责任公司	半氟化化合物和其组合物
USRE50060E1 (en)	2016-06-23	2024-07-30	Novaliq Gmbh	Topical administration method
ES2969758T3 (es)	2016-09-22	2024-05-22	Novaliq Gmbh	Composiciones farmacéuticas para usar en la terapia de la blefaritis
KR20190057338A (ko) *	2016-09-23	2019-05-28	노바리크 게엠베하	시클로스포린을 포함하는 안과 조성물
BR112019006194A2 (pt) *	2016-09-28	2019-06-18	Novaliq Gmbh	composições que compreendem um ligante de ligação ao receptor de canabinóides
WO2018114557A1 (fr) *	2016-12-22	2018-06-28	Novaliq Gmbh	Compositions comprenant du tacrolimus pour le traitement de maladies oculaires inflammatoires intraoculaires
ES2819005T3 (es) *	2016-12-23	2021-04-14	Novaliq Gmbh	Composición oftálmica para el tratamiento de la enfermedad del ojo seco
AU2018205253B2 (en)	2017-01-06	2022-01-13	Palvella Therapeutics, Inc.	Anhydrous compositions of mTOR inhibitors and methods of use
EP3612228B1 (fr) *	2017-04-21	2023-08-23	Dermaliq Therapeutics, Inc.	Compositions d'iode
EP3619186B1 (fr)	2017-05-05	2021-02-17	Novaliq GmbH	Procédé de production d'alcanes semi-fluorés
US11278503B2 (en)	2017-05-12	2022-03-22	Novaliq Gmbh	Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
MX2020003534A (es)	2017-09-27	2020-07-29	Novaliq Gmbh	Composiciones oftalmicas que comprenden latanoprost para usarse en el tratamiento de las enfermedades oculares.
CN111182893A (zh)	2017-10-04	2020-05-19	诺瓦利克有限责任公司	包含f6h8的眼用组合物
AU2019228119A1 (en)	2018-03-02	2020-09-10	Novaliq Gmbh	Pharmaceutical compositions comprising nebivolol
IL276888B2 (en)	2018-03-28	2024-12-01	Novaliq Gmbh	Pharmaceutical composition comprising timolol
EP3784246A1 (fr)	2018-04-27	2021-03-03	Novaliq GmbH	Compositions ophtalmiques comprenant du tafluprost pour le traitement du glaucome
EP3817743A4 (fr)	2018-07-02	2022-07-06	Palvella Therapeutics, Inc.	Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
KR20210080388A (ko)	2018-09-22	2021-06-30	노바리크 게엠베하	안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물
EP3856124A1 (fr)	2018-09-27	2021-08-04	Novaliq GmbH	Réparation de la barrière lipidique
CN112823020A (zh)	2018-10-12	2021-05-18	诺瓦利克有限责任公司	用于治疗干眼病的眼用组合物
US20220008397A1 (en) *	2019-01-21	2022-01-13	Novaliq Gmbh	Pharmaceutical composition for the treatment of ocular neovascularisation
EP3923907B1 (fr)	2019-02-13	2024-09-25	Novaliq GmbH	Compositions et procédés pour le traitement de la néovascularisation oculaire
AU2020281641B2 (en)	2019-05-24	2025-09-11	Novaliq Gmbh	Ophthalmic composition for the treatment of ocular allergy
AU2020340561B2 (en)	2019-09-06	2026-01-22	Novaliq Gmbh	Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (fr)	2019-09-13	2021-03-18	Minas Coroneo	Distributeur de gouttes oculaires
WO2021191273A1 (fr)	2020-03-24	2021-09-30	Hovione Scientia Limited	Compositions destinées à être utilisées dans le traitement d'un dysfonctionnement de la glande de meibomius
US11191751B1 (en) *	2020-10-08	2021-12-07	Ads Therapeutics Llc	Topical ophthalmological atropine free base compositions
WO2024170514A1 (fr) *	2023-02-13	2024-08-22	Novaliq Gmbh	Composition ophtalmique pour préparation de chirurgie oculaire chez des patients atteints d'une maladie de surface oculaire
AU2023270196B2 (en) *	2023-11-20	2025-06-26	Dyer, Gordon Wayne DR	Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (ko)	1987-09-03	1992-05-04	유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드	점안 싸이클로스포린(cyclosporin)의 조성물
US5874481A (en) *	1995-06-07	1999-02-23	Alliance Pharmaceutical Corp.	Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) *	1995-09-29	1999-09-23	H Meinert	Verwendung fluorierter Alkane
DE19861012A1 (de) *	1998-03-18	1999-09-30	Pharm Pur Gmbh	Behandlungsmittel für die Ophthalmologie
CN1190194C (zh) *	1999-04-30	2005-02-23	苏坎波公司	用于治疗干眼的大环内酯化合物的应用
DE19938668B4 (de) *	1999-08-14	2006-01-26	Bausch & Lomb Inc.	Tränenersatzmittel
US20030018044A1 (en) *	2000-02-18	2003-01-23	Peyman Gholam A.	Treatment of ocular disease
ES2387619T3 (es) *	2004-04-19	2012-09-27	Centre National De La Recherche Scientifique (Cnrs)	Suplementos de tensioactivos pulmonares
JP2008501806A (ja) *	2004-06-08	2008-01-24	オキュラリスファーマ，インコーポレイテッド	疎水性眼用組成物および使用方法
DE102007055046A1 (de) *	2007-11-19	2009-05-28	Fluoron Gmbh	Infusionslösung
EP2110126B9 (fr)	2008-04-18	2012-09-19	Novaliq GmbH	Utilisation pour inhalation et instillation d'alcanes semifluorées comme support de matière active dans la zone intrapulmonaire

2009
- 2009-12-14 EP EP09015423A patent/EP2335735A1/fr not_active Withdrawn
2010
- 2010-12-13 PL PL10790775T patent/PL2512515T3/pl unknown
- 2010-12-13 CA CA2776860A patent/CA2776860C/fr active Active
- 2010-12-13 BR BR112012014190A patent/BR112012014190B8/pt active IP Right Grant
- 2010-12-13 DK DK10790775.0T patent/DK2512515T3/en active
- 2010-12-13 BR BR122020020872-4A patent/BR122020020872B1/pt active IP Right Grant
- 2010-12-13 WO PCT/EP2010/069495 patent/WO2011073134A1/fr not_active Ceased
- 2010-12-13 ES ES10790775.0T patent/ES2449308T3/es active Active
- 2010-12-13 JP JP2012542577A patent/JP5663595B2/ja active Active
- 2010-12-13 AU AU2010333039A patent/AU2010333039B2/en active Active
- 2010-12-13 BR BR122017018955-7A patent/BR122017018955B1/pt active IP Right Grant
- 2010-12-13 KR KR1020127018066A patent/KR101652714B1/ko active Active
- 2010-12-13 IN IN3128DEN2012 patent/IN2012DN03128A/en unknown
- 2010-12-13 EP EP10790775.0A patent/EP2512515B1/fr active Active
- 2010-12-13 CN CN201080055507.7A patent/CN102652022B/zh active Active
- 2010-12-13 US US13/513,886 patent/US8614178B2/en active Active
- 2010-12-13 MX MX2012006720A patent/MX2012006720A/es active IP Right Grant
- 2010-12-13 PT PT107907750T patent/PT2512515E/pt unknown
- 2010-12-13 KR KR1020167023214A patent/KR101722039B1/ko active Active
- 2010-12-13 CA CA2941956A patent/CA2941956C/fr active Active
2014
- 2014-10-01 JP JP2014203406A patent/JP6096731B2/ja active Active
2016
- 2016-12-22 JP JP2016248533A patent/JP6397472B2/ja active Active
2018
- 2018-08-31 JP JP2018163569A patent/JP2019006803A/ja active Pending
- 2018-12-28 JP JP2018248700A patent/JP6731039B2/ja active Active

Also Published As

Publication number	Publication date
JP6731039B2 (ja)	2020-07-29
JP2017078086A (ja)	2017-04-27
EP2335735A1 (fr)	2011-06-22
EP2512515B1 (fr)	2013-12-25
CN102652022A (zh)	2012-08-29
HK1172269A1 (en)	2013-04-19
US20120244177A1 (en)	2012-09-27
JP2015028064A (ja)	2015-02-12
EP2512515A1 (fr)	2012-10-24
BR122020020872B1 (pt)	2021-09-08
US8614178B2 (en)	2013-12-24
KR101722039B1 (ko)	2017-03-31
KR20160105533A (ko)	2016-09-06
BR112012014190A2 (pt)	2016-05-31
MX2012006720A (es)	2012-07-30
CN102652022B (zh)	2014-12-17
CA2776860C (fr)	2016-10-25
BR122017018955B1 (pt)	2022-03-08
JP2013513586A (ja)	2013-04-22
PT2512515E (pt)	2014-03-04
CA2941956C (fr)	2018-09-04
BR112012014190B8 (pt)	2021-05-25
CA2776860A1 (fr)	2011-06-23
DK2512515T3 (en)	2014-03-10
CA2941956A1 (fr)	2011-06-23
AU2010333039B2 (en)	2014-08-28
JP5663595B2 (ja)	2015-02-04
JP2019006803A (ja)	2019-01-17
AU2010333039A1 (en)	2012-07-12
KR101652714B1 (ko)	2016-09-01
ES2449308T3 (es)	2014-03-19
JP2019070003A (ja)	2019-05-09
JP6397472B2 (ja)	2018-09-26
KR20120115977A (ko)	2012-10-19
WO2011073134A1 (fr)	2011-06-23
JP6096731B2 (ja)	2017-03-15
BR112012014190B1 (pt)	2021-03-02
PL2512515T3 (pl)	2014-05-30

Publication	Publication Date	Title
MX2012006720A (es)	2012-07-30	Composicion farmceutica para el tratamiento de sindrome del ojo seco.
MX389597B (es)	2025-03-20	Inhibidores de cdk2/4/6 de piridopirimidinona.
WO2014047427A3 (fr)	2015-07-16	Inhibiteurs de la mcl-1 à base de benzofurane, de benzothiophène et d'indole substitués
NZ708593A (en)	2018-01-26	Novel pyrazole derivative
PH12014500943A1 (en)	2014-06-30	Combination treatment of cancer
EP4342540A3 (fr)	2024-05-29	Dérivés hétérocyclyle substitués en tant qu'inhibiteurs de cdk
EP4292662A3 (fr)	2024-02-21	Inhibiteurs d'indoles mcl-1 substitués
WO2015070224A3 (fr)	2015-08-13	Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
CU20160109A7 (es)	2017-02-02	Compuestos de indazol como inhibidores de irak4
MX2016011468A (es)	2017-01-23	Inhibidores de calicreína plasmática humana.
MX2013012776A (es)	2013-11-21	Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina.
DOP2019000275A (es)	2019-11-15	Nuevos derivados de pirazol bicíclicos
EP4403552A3 (fr)	2024-10-16	Inhibiteurs de hsp90 c-terminaux
UA103930C2 (ru)	2013-12-10	Соединения и композиция для лечения паразитарных болезней
EP4414376A3 (fr)	2024-11-06	Nouveau depsipeptide et ses utilisations
CO6602152A2 (es)	2013-01-18	En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga.
EP3216798A3 (fr)	2017-10-25	Composés kétolides
MX341220B (es)	2016-08-10	Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
EP4299126A3 (fr)	2024-04-03	Modulateurs allostériques positifs au gaba restreints au système nerveux périphérique pour le traitement du syndrome du côlon irritable et autres affections du système nerveux périphérique
PH12013500644A1 (en)	2013-05-20	Co-crystals and salts of ccr3-inhibitors
CL2012003521A1 (es)	2013-02-15	Derivado piperidino (r)-n-((r)-1-((3s-4s)-4-(4-clorofenil)-3,4-dihidroxi-3-metilpiperidin-1-il)-3-metil-1-oxobutan-2-il)-3,3-difluorociclopentanocarboxamida, modulador receptor quimiocinas; composicion farmaceutica; y uso del compuesto y su composicion en enfermedades inflamatorias y autoinmunitarias, entre otras.
MX2024010625A (es)	2024-09-05	Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
MX2020012989A (es)	2021-02-16	Agente terapeutico para la fibrosis.
IN2014CN02908A (fr)	2015-07-03
NZ737892A (en)	2018-09-28	Muscarinic m1 receptor positive allosteric modulators